The pooled prevalence of pulmonary embolism in patients with COVID-19
- PDF / 1,518,955 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 56 Downloads / 169 Views
LETTER
The pooled prevalence of pulmonary embolism in patients with COVID‑19 Li Shi1, Jie Xu1, Guangcai Duan1, Haiyan Yang1* and Yadong Wang2* © 2020 Springer-Verlag GmbH Germany, part of Springer Nature
Dear Editor, Shah et al. observed an awfully high prevalence (53.5%) of pulmonary embolism (PE) among 30 intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19) in Oxford, UK [1]. Although several studies have focused on this cardiovascular complication of PE in COVID-19 patients, the prevalence of PE varies from study to study [2–4]. Therefore, we explored the pooled prevalence of PE in COVID-19 patients by a quantitative meta-analysis. Details of our study are shown in Supplementary file 1. PubMed, EMBASE and Web of Science were reviewed up to August 12th, 2020 to identify relevant studies. Studies reporting the prevalence of confirmed PE in COVID19 patients and with the sample size ≥ 30 were included. The pooled prevalence and corresponding 95% confidence interval (CI) were used to assess the combined effects. An additional analysis comparing the prevalence of PE in COVID-19 patients admitted to ICU and nonICU was conducted. Heterogeneity between studies was estimated with I2 statistic and Cochran’s Q (reported as χ2 and P values) [5]. Subgroup analysis and meta-regression analysis were conducted by country, study design, sample size, quality score, PE diagnosis and prevalence of prophylactic anticoagulation to explore possible sources of heterogeneity. Among 1981 potentially related studies, 49 articles (52 studies) comprising 20,523 COVID-19 patients were enrolled in this meta-analysis after rigorous screening *Correspondence: [email protected]; [email protected] 1 Department of Epidemiology, College of Public Health, Zhengzhou University, No. 100 of Science Avenue, Zhengzhou 450001, China 2 Department of Toxicology, Henan Center for Disease Control and Prevention, No. 105 of South Nongye Road, Zhengzhou 450016, China Full author information is available at the end of the article
(Suppl. File 2, Fig. S1). The principal characteristics and details about the PE diagnosis of the included studies were shown in Supplementary file 2, Table S4 and Table S5. The pooled prevalence of PE in COVID-19 patients was 8% (95% CI 6–11%; χ2 = 1259.68, P
Data Loading...
